Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

• Status: Terminated
• Trial end date: 2018-07-23
• Target enrollment: 0
• Participant gender: All

Summary

The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH
• Treatments: Liraglutide; Lixisenatide

Criteria

Inclusion Criteria:

• Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.

• Male or female aged 18-65 years (both inclusive)

• T2DM diagnosis

Exclusion Criteria:

• Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics

• Use of GLP-1 mimetics or DPP-IV inhibitors

• Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%